Bellicum Pharmaceuticals, Inc. BLCM
Day range unavailable
52-week range unavailable
- Market cap
- 3.51M
- Revenue (ttm)
- 1.51M
- Shares out
- 9.50M
- Forward P/E
- -0.39
- Beta
- 1.51
- Analysts
- Hold
- Price target
- 5.00 (+6589.0%)
- Earnings date
- Mar 5, 2024
2Y -1.4153 (-94.98%)
Key statistics
- Enterprise value
- 10.58M
- PEG ratio
- 0.00
- Price / sales
- 2.33
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -17.43M
- Total cash
- 15.40M
- Total debt
- 0
- Return on equity
- -106.13%
- Short % of float
- 17.08%
- 50-day average
- 0.524896
- 200-day average
- 0.816478
Analyst view
Consensus: hold
- Strong buy5
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 5, 2024
Expected Mar 5, 2024. Consensus EPS estimate -0.29.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 5, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 16, 2022 | Ladenburg Thalmann | init | — | Buy |
| Oct 30, 2020 | Wells Fargo | down | Overweight | Equal-Weight |
| Nov 25, 2020 | Raymond James | main | — | Outperform |
| Nov 25, 2020 | Citigroup | main | Buy | Buy |
| Nov 25, 2020 | Wells Fargo | up | Market Perform | Outperform |
| Nov 25, 2020 | Wells Fargo | down | Outperform | Market Perform |
About Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bellicum.com
News
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
Crude Oil Rises Over 2%; US Wholesale Inventories Unchanged For March - Why Bellicum Pharmaceuticals Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Stocks That Hit 52-Week Lows On Friday - Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Monday
Your note
Sign in to keep a note on BLCM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROWN JAMES FARRELL | Director | Conversion of Exercise of derivative security | Jan 3, 2022 | 28,384 |
| DALY JAMES M. | Director | Conversion of Exercise of derivative security | Jan 2, 2023 | 109,873 |
| DAVIS STEPHEN R | Director | Conversion of Exercise of derivative security | Jan 2, 2023 | 136,854 |
| FAIR RICHARD A. | Chief Executive Officer | Purchase | Mar 16, 2020 | 0 |
| FOSTER AARON E | Officer | Conversion of Exercise of derivative security | Jan 2, 2020 | 7,281 |
| HUBER REID M. | Director | Conversion of Exercise of derivative security | Jan 2, 2023 | 153,179 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ikarian Capital, LLC | 4.72% | 448,101 | 165.80K | Mar 30, 2023 |
| Long Focus Capital Management, LLC | 3.45% | 327,692 | 121.25K | Mar 30, 2023 |
| Baker Brothers Advisors, LLC | 2.62% | 249,123 | 92.17K | Mar 30, 2023 |
| Blackrock Inc. | 0.80% | 75,753 | 28.03K | Mar 30, 2023 |
| Geode Capital Management, LLC | 0.77% | 72,770 | 26.92K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 0.70% | 66,309 | 24.53K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.03% | 92,861 | 34.36K | Dec 30, 2022 |
| Vanguard Total Stock Market Index Fund | 0.96% | 86,517 | 32.01K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.41% | 37,163 | 13.75K | Feb 27, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.25% | 22,867 | 8.46K | Feb 27, 2023 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.07% | 6,714 | 2.48K | Feb 27, 2023 |
| Tekla Life Sciences Investors | 0.07% | 6,000 | 2.22K | Dec 30, 2022 |